Literature DB >> 22344959

Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease?

Carsten Büning1, Nora Geissler, Matthias Prager, Andreas Sturm, Daniel C Baumgart, Janine Büttner, Sabine Bühner, Verena Haas, Herbert Lochs.   

Abstract

BACKGROUND: A disturbed epithelial barrier could play a pivotal role in ulcerative colitis (UC). We performed a family-based study analyzing in vivo gastrointestinal permeability in patients with UC, their healthy relatives, spouses, and controls.
METHODS: In total, 89 patients with UC in remission, 35 first-degree relatives (UC-R), 24 nonrelated spouses (UC-NR), and 99 healthy controls (HC) were studied. Permeability was assessed by a sugar-drink test using sucrose (gastroduodenal permeability), lactulose/mannitol (intestinal permeability), and sucralose (colonic permeability). Data were correlated with clinical characteristics including medical treatment.
RESULTS: Increased intestinal permeability was detected significantly more often in UC patients in remission (25/89, 28.1%) compared with HC (6/99, 6.1%; P < 0.001). Similar results were obtained in UC-R (7/35, 20.0%; P = 0.01 compared with HC) regardless of sharing the same household with the patients or not. No difference was found between UC-NR (3/24, 12.5%) and HC. Notably, in UC patients increased intestinal permeability was found in 12/28 patients (42.9%) with pancolitis, 7/30 (23.3%) patients with left-sided colitis, and in 2/19 (10.5%) patients with proctitis (P = 0.04). Gastroduodenal and colonic permeability were similar in all groups. Among patients on azathioprine, increased intestinal permeability was only seen in 1/18 (5.6%) patients. In contrast, in 24/70 (34.3%) patients without azathioprine, an increased intestinal permeability was found (P = 0.005).
CONCLUSIONS: An increased intestinal but not colonic permeability was found in UC patients in clinical remission that could mark a new risk factor for extensive disease location. Similar findings in healthy relatives but not spouses suggest that this barrier defect is genetically determined.
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22344959     DOI: 10.1002/ibd.22909

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  29 in total

Review 1.  The digestive neuronal-glial-epithelial unit: a new actor in gut health and disease.

Authors:  Michel Neunlist; Laurianne Van Landeghem; Maxime M Mahé; Pascal Derkinderen; Stanislas Bruley des Varannes; Malvyne Rolli-Derkinderen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-11-20       Impact factor: 46.802

2.  Chlorogenic acid decreased intestinal permeability and ameliorated intestinal injury in rats via amelioration of mitochondrial respiratory chain dysfunction.

Authors:  Yan Zhou; Zheng Ruan; Lili Zhou; Yuhui Yang; Shumei Mi; Zeyuan Deng; Yulong Yin
Journal:  Food Sci Biotechnol       Date:  2016-02-29       Impact factor: 2.391

3.  Intestinal Alkaline Phosphatase Regulates Tight Junction Protein Levels.

Authors:  Wei Liu; Dong Hu; Haizhong Huo; Weifeng Zhang; Fatemeh Adiliaghdam; Sarah Morrison; Juan M Ramirez; Sarah S Gul; Sulaiman R Hamarneh; Richard A Hodin
Journal:  J Am Coll Surg       Date:  2015-12-18       Impact factor: 6.113

Review 4.  IBS and IBD - separate entities or on a spectrum?

Authors:  Robin Spiller; Giles Major
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-26       Impact factor: 46.802

Review 5.  The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease.

Authors:  Tim Vanuytsel; Séverine Vermeire; Isabelle Cleynen
Journal:  Tissue Barriers       Date:  2013-12-10

Review 6.  Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases.

Authors:  Craig Sturgeon; Alessio Fasano
Journal:  Tissue Barriers       Date:  2016-10-21

7.  Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution.

Authors:  Arseima Y Del Valle-Pinero; Hendrick E Van Deventer; Nicolaas H Fourie; Angela C Martino; Nayan S Patel; Alan T Remaley; Wendy A Henderson
Journal:  Clin Chim Acta       Date:  2013-01-14       Impact factor: 3.786

8.  Association of MYO9B gene polymorphisms with inflammatory bowel disease in Chinese Han population.

Authors:  Jing Hu; Qiao Mei; Jian Huang; Nai-Zhong Hu; Xiao-Chang Liu; Jian-Ming Xu
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

9.  Androgen Deprivation Therapy and the Incidence of Inflammatory Bowel Disease in Patients With Prostate Cancer.

Authors:  Adi J Klil-Drori; Koray Tascilar; Hui Yin; Armen Aprikian; Alain Bitton; Laurent Azoulay
Journal:  Am J Epidemiol       Date:  2016-06-06       Impact factor: 4.897

Review 10.  Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view.

Authors:  Mi-Kyung Sung; Mi-Young Park
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.